

In place of
PTO-1449 FormU. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT BY
APPLICANT

(use as many sheets as necessary)

Complete if Known


Application Number	09/847,601
Filing Date	May 1, 2001
Applicant(s)	Lewin et al.
Art Unit	1632
Examiner Name	Unknown

SHEET

1

OF

2

Attorney Docket Number
36689.140

U. S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
KC		4,683,195	07-28-1987	Mullis et al.
		4,683,202	07-28-1987	Mullis
		4,800,159	01-24-1989	Mullis et al.
		4,883,750	11-28-1989	Whiteley et al.
		5,297,721	03-29-1994	Schneider et al.
		5,334,711	08-02-1994	Sproat et al.
		5,354,855	10-11-1994	Cech et al.
		5,455,166	10-03-1995	Walker
		5,631,359	05-20-1997	Chowrira et al.
		5,648,211	07-15-1997	Fraiser et al.
		5,712,124	01-27-1998	Walker
		5,744,311	04-28-1998	Fraiser et al.
		6,225,291	05-01-2001	Lewin et al.
		6,943,153	09-13-2005	Manning et al.
		2001/0034054 A1	10-25-2001	Dwarki et al.
		2001/0051611 A1	12-13-2001	Srivastava et al.
		2002/0132336 A1	09-19-2002	Dwarki et al.
		2002/0194630 A1	12-19-2002	Manning et al.
		2003/0166284 A1	09-04-2003	Srivastava et al.

Examiner's Initial	Cite No.	Foreign Patent Document (Country Code - Number - Kind)	Publication Date MM-DD-YYYY	Patentee or Applicant of Cited Document	Translation Y/N
KC		EP 0320308	11-03-1993	Abbott Laboratories	
		EP 0329822	06-08-1994	Cangene Corporation	
		EP 0360257	03-28-1990	The Board of Regents for Northern Illinois University Biotechnology Research and Development Corp. Inc.	
		GB 2202328	09-21-1988	Orion-Yhtyma Oy	
		WO 87/06270	10-22-1987	The Salk Institute for Biological Studies	
		WO 88/10315	12-29-1988	Siska Diagnostics, Inc.	
		WO 89/06700	07-27-1989	Genetech, Inc.	
		WO 89/09284	10-05-1989	University of Iowa Research Foundation	
		WO 90/07641	07-12-1990	Sundstrand Corporation	
		WO 91/03162	03-21-1991	City of Hope	
		WO 92/07065	04-30-1992	Maxplanck-Gesellschaft Zur Förderung der Wissenschaften E.V.	
		WO 93/15187	08-05-1993	Massachusetts Institute of Technology	
		WO 93/23569	11-25-1993	Ribozyme Pharmaceuticals, Inc.	
		WO 94/02595	02-03-1994	Ribozyme Pharmaceuticals, Inc.	
		WO 94/13688	06-23-1994	Gene Shears Pty. Limited	
		WO 00/54813 A2	09-21-2000	Manning et al.	
		WO 02/24234 A2	03-28-2002	McGee et al.	
		WO 02/088320 A2	11-07-2002	University of Florida	

Examiner Signature	/Kimberly Chong/	Date Considered	09/11/2006
--------------------	------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

In place of PTO-1449 Form	U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/847,601
				Filing Date	May 1, 2001
				Applicant(s)	Lewin et al.
				Art Unit	1632
				Examiner Name	Unknown
SHEET	2	OF	2	Attorney Docket Number	36689.140

NON-PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item, date, page(s), volume-issue number(s), publisher, city/country where published
KC		AFZAL et al., "Reduction on Preretinal Neovascularization by Ribozymes that Cleave the A _{2B} Adenosine Receptor mRNA," <i>Circulation Research</i> , 93, September 23, 2003.
		BERGSLAND et al., "Update on Clinical Trials Targeting Vascular Endothelial Growth Factor in Cancer," <i>Am. J. Health Syst. Pharm.</i> , 61(5):S12-S20, November 2004.
		BLALOCK et al., "Hammerhead ribozyme targeting connective tissue growth factor mRNA blocks transforming growth factor-beta mediated cell proliferation," <i>Experimental Eye Research</i> , 78:1127-1136, 2004.
		CORDIERO et al., "Molecular Therapy in Ocular Wound Healing," <i>BJO Online</i> , 83:1219-1224, 1999.
		FARRAR et al., "On the Genetics of Retinitis Pigmentosa and on Mutation-Independent Approaches to Therapeutic Intervention," <i>EMBO J.</i> , 21(5):857-864, 2002.
		FRITZ et al., "Design and Validation of Therapeutic Hammerhead Ribozymes for Autosomal Dominant Diseases," <i>Methods Mol. Bio.</i> , 252:221-36, 2004.
		FRITZ et al., "Designing and Characterizing Hammerhead Ribozymes for Use in AAV Vector-Mediated Retinal Gene Therapies," <i>Methods Enzymol.</i> , 346:358-77, 2002.
		FRITZ et al., "Development of Hammerhead Ribozymes to Modulate Endogenous Gene Expression For Functional Studies," <i>Methods</i> , 28(2):276-85, October 2002.
		GORBATYUK et al., "Knockdown of Wild-Type Mouse Rhodopsin Using an AAV Vectored Ribozyme as Part of an RNA Replacement Approach," <i>Mol. Vis.</i> , 11:648:56, August 29, 2005.
		HAUSWIRTH et al., "Range of Retinal Disease Potentially Treatable by AAV-vectored Gene Therapy," <i>Novartis Found. Symp.</i> , 255:179-194, 2004.
		HAUSWIRTH et al., "Ribozyme Gene Therapy for Autosomal Dominant Retinal Disease," <i>Clin. Chem. Lab. Med.</i> 2000, 38(2):147-153, 2000.
		HAUSWIRTH et al., "Ribozyme Uses in Retinal Gene Therapy," <i>Prog. Retin. Eye Res.</i> , 19(6):689-710, November 2000.
		LEWIN et al., "Gene Therapy for Autosomal Dominant Disorders of Keratin," <i>J. Investig. Dermatol. Symp. Proc.</i> , 10(1):47-61, 2005.
		LEWIN et al., "Ribozyme Gene Therapy: Applications for Molecular Medicine," <i>Trends Mol. Med.</i> , 7(5):221-8, May 2001.
		LIU et al., "Ribozyme Knockdown for the Gamma-Subunit of Rod cGMP Phosphodiesterase Alters the ERG and Retinal Morphology In Wild-Type Mice," <i>Invest. Ophthalmol. Vis. Sci.</i> , 46(10):3836-44, October 2005.
		QI et al., "Optic Neuropathy Induced by Reductions in Mitochondrial Superoxide Dismutase," <i>Invest. Ophthalmol. Vis. Sci.</i> , 44(3): 1088-96, March 2003.
		QI et al., "SOD2 Gene Transfer Protects Against Optic Neuropathy Induced By Deficiency of Complex I," <i>Ann. Neurol.</i> , 56(2):182-91, August 2004.
		QI et al., "Suppression of Complex I Gene Expression Induces Optic Neuropathy," <i>Ann. Neurol.</i> , 53(2):198-205, February 2003.
		SHAW et al., "An Allele-Specific Hammerhead Ribozyme Gene Therapy For a Porcine Model of Autosomal Dominant Retinitis Pigmentosa," <i>Mol. Vis.</i> , 7:6-13, January 2001.
		SHAW et al., "Decreased Expression of the Insulin-like Growth Factor 1 Receptor by Ribozyme Cleavage," <i>IOVS</i> , 44 (9): 4105-4113, September 2003.
		SHAW et al., "Ribozymes in Treatment of Inherited Retinal Disease," <i>Methods Enzymol.</i> , 316:761-76, 2000.
		International Search Report PCT/US02/13679; April 04, 2005.
		International Preliminary Examination Report PCT/US02/1379; September 15, 2005.

Examiner Signature	/Kimberly Chong/	Date Considered	09/11/2006
--------------------	------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
4300.014100Serial No.
09/847,601

Applicants

Alfred S. Lewin, Lynn C. Shaw and Maria B. Grant

Filing Date:
May 1, 2001Group:
1632U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 1-5

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
KC	A1	4,987,071	01/22/91	Cech <i>et al.</i>			
	A2	5,037,746	08/06/91	Cech <i>et al.</i>			
	A3	5,093,246	03/03/92	Cech <i>et al.</i>			
	A4	5,116,742	05/26/92	Cech <i>et al.</i>			
	A5	5,498,539	03/12/96	Harrison <i>et al.</i>			
	A6	5,639,655	06/17/97	Thompson <i>et al.</i>			
↓	A7	5,646,020	07/08/97	Swiggen <i>et al.</i>			
↓	A8	5,646,031	07/08/97	DeYoung <i>et al.</i>			

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
KC	B1	WO 95/04142	02/09/95	PCT			
↓	B2	WO 97/11169	03/27/97	PCT			
↓	B3	WO 97/32024	09/04/97	PCT			
↓	B4	WO 98/48009	10/29/98	PCT			
↓	B5	WO 98/48027	10/29/98	PCT			

EXAMINER: /Kimberly Chong/

DATE CONSIDERED: 09/11/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
4300.014100
Serial No.
09/847,601Applicants
Alfred S. Lewin, Lynn C. Shaw and Maria B. GrantFiling Date:
May 1, 2001
Group:
1632

U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-5</i>
--	---	----------------------------------

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
KC	C1	Alfione <i>et al.</i> , "In vivo model of adeno-associated virus vector persistence and rescue," <i>Journal of Virology</i> , 70:3235-3241, 1996.
	C2	Altschuler <i>et al.</i> , "A method for generating transcripts defined with 5' and 3' termini by autolytic processing," <i>Gene</i> , 122:85-90, 1992.
	C3	Al-Ubaidi <i>et al.</i> , "Photoreceptor degeneration induced by the expression of simian virus 40 large tumor antigen in the retina of transgenic mice," <i>Proc. Natl. Acad. Sci. USA</i> , 89:1194-1198, 1992.
	C4	Cech, "Self-splicing of Group I introns," <i>Annu. Rev. Biochem.</i> , 59:543-568, 1990.
	C5	Chakravathy <i>et al.</i> , "Nitric oxide synthase activity and expression in retinal capillary endothelial cells and pericytes," <i>Curr. Eye Res.</i> , 14(4):285-294, 1995.
	C6	Chen <i>et al.</i> , "The human blue opsin promoter directs transgene expression in short-wave cones and bipolar cells in the mouse retina," <i>Proc. Natl. Acad. Sci. USA</i> , 91(7):2611-2615, 1994.
	C7	Chiu <i>et al.</i> , "A sequence upstream of the mouse blue visual pigment gene directs blue cone-specific transgene expression in mouse retinas," <i>Visual Neuroscience</i> , 11(4):773-780, 1994.
	C8	Cipolla, Porter and Osol, "High glucose concentrations dilate cerebral arteries and diminish myogenic tone through an endothelial mechanism," <i>Stroke</i> , 28(2):405-411, 1997.
	C9	Cosentino <i>et al.</i> , "High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells," <i>Circulation</i> , 96(1):25-28, 1997.
	C10	Crystal, "Transfer of genes to humans: early lessons and obstacles to success," <i>Science</i> , 270:404-410, 1995.
	C11	Daiger, Sullivan and Rodriguez, "Correlation of phenotype with genotype in inherited retinal degeneration," <i>Behavioral and Brain Sciences</i> , 18:452-467, 1995.
	C12	DesJardin and Hauswirth, "Developmentally important DNA elements within the bovine opsin upstream region," <i>Investigative Ophthalmology & Visual Science</i> , 37(1):154-165, 1996.
▼	C13	Drenser <i>et al.</i> , "Ribozyme mediated degradation of the P23H and S334Ter mutant mRNAs associated with ADRP," <i>Investigative Ophthalmology & Visual Science</i> , 38(4):S441, Abstract 2085, 1997 (Annual Mtg. Of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, USA, May 11-16, 1997).


EXAMINER:

/Kimberly Chong/

DATE CONSIDERED:

09/11/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
4300.014100Serial No.
09/847,601

Applicants

Alfred S. Lewin, Lynn C. Shaw and Maria B. Grant

Filing Date:
May 1, 2001Group:
1632U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 1-5

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
KC	C14	Drenser <i>et al.</i> , "Ribozyme mediated destruction of an messenger-RNA causing retinitis pigmentosis," <i>Investigative Ophthalmology & Visual Science</i> , 37(3):S10, Abstract 42, 1996.
	C15	Drenser <i>et al.</i> , "Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa," <i>Investigative Ophthalmology & Visual Science</i> , 39(5):681-689, 1998.
	C16	Flannery <i>et al.</i> , "Efficient photoreceptor-targeted gene expression <i>in vivo</i> by recombinant adeno-associated virus," <i>Proc. Natl. Acad. Sci. USA</i> , 94(13):6916-6921, 1997.
	C17	Flotte <i>et al.</i> , "Stable <i>in vivo</i> expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector," <i>Proc. Natl. Acad. Sci. USA</i> , 90(22):10613-10617, 1993.
	C18	Gade <i>et al.</i> , "Nitric oxide mediates hyperglycemia-induced defective migration in cultured endothelial cells," <i>Journal of Vascular Surgery</i> , 26(2):319-326, 1997.
	C19	Goldstein, Ostwal and Roth, "Nitric oxide: a review of its role in retinal function and disease," <i>Vision Res.</i> , 36(18):2979-2994, 1996.
	C20	Hangai <i>et al.</i> , "Inducible nitric oxide synthase in retinal ischemia-reperfusion injury," <i>Exp. Eye Res.</i> , 63(5):501-509, 1996.
	C21	Hauswirth <i>et al.</i> , "Adeno-associated virus delivery of an opsin promoter driven reporter gene to the mouse and rabbit retina," <i>Gene Therapy</i> , 2(Supp. 1):S2, Abstract 6, 1995.
	C22	International Search Report dated February 1, 1999 (PCT/US98/07968) (4300.011510).
	C23	International Search Report dated February 16, 1999 (PCT/US98/08003) (4300.011410).
	C24	Kaplitt <i>et al.</i> , "Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain," <i>Nature Genetics</i> , 8:148-154, 1994.
	C25	Kessler <i>et al.</i> , "Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein," <i>Proc. Natl. Acad. Sci. USA</i> , 93:14082-14087, 1996.
	C26	Kido <i>et al.</i> , "Use of a retroviral vector with an internal opsin promoter to direct gene expression to retinal photoreceptor cells," <i>Current Eye Research</i> , 15:833-844, 1996.
✓	C27	Koizumi, Kiroyuki and Eiko, "Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene," <i>Gene</i> , 117:179-184, 1992.

EXAMINER: /Kimberly Chong/

DATE CONSIDERED: 09/11/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

SEP 20 2001

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No. 4300.014100 Serial No. 09/847,601

Applicants

Alfred S. Lewin, Lynn C. Shaw and Maria B. Grant

Filing Date: May 1, 2001 Group: 1632

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1-5

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
KC	C28	Komatsu <i>et al.</i> , "A new type of hairpin ribozyme consisting of three domains," <i>Biochemistry</i> , 36(32):9935-9940, 1997.
	C29	Lem <i>et al.</i> , "Tissue-specific and developmental regulation of rod opsin chimeric genes in transgenic mice," <i>Neuron</i> , 6:201-210, 1991.
	C30	Lewin <i>et al.</i> , "Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa," <i>Nature Medicine</i> , 4(8):967-971, 1998.
	C31	Li <i>et al.</i> , "Cone-specific gene transfer and expression using human red/green opsin promoter in a recombinant AAV," <i>IOVS</i> , 39(4):S721, 3311-B137, 1998.
	C32	Little and Lee, "Generation of a mammalian cell line deficient in glucose-regulated protein stress induction through targeted ribozyme driven by a stress-inducible promoter," <i>The Journal of Biological Chemistry</i> , 270(16):9526-9534, 1995.
	C33	Millington-Ward <i>et al.</i> , "Strategies <i>in vivo</i> for gene therapies directed to dominant mutations," <i>Human Molecular Genetics</i> , 6(9):1415-1426, 1997.
	C34	Ojwang <i>et al.</i> , "Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme," <i>Proc. Natl. Acad. Sci. USA</i> , 89:10802-10806, 1992.
	C35	Ostwald <i>et al.</i> , "Effect of nitric oxide synthase inhibition on blood flow after retinal ischemia in cats," <i>Investigative Ophthalmology & Visual Science</i> , 36(12):2396-2403, 1995.
	C36	Raymond <i>et al.</i> , "Expression of rod and cone visual pigments in goldfish and zebrafish: a rhodopsin-like gene is expressed in cones," <i>Neuron</i> , 10:1161-1174, 1993.
	C37	Ross <i>et al.</i> , "Gene therapy in the United States: A five year status report," <i>Human Gene Therapy</i> , 7:1781-1790, 1996.
	C38	Sharma <i>et al.</i> , "Enhance expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels: Possible mediation via protein kinase C ⁺ ," <i>Biochem. Biophys. Res. Comm.</i> , 207(1):80-88, 1995.
	C39	Steinberg <i>et al.</i> , "Transgenic rat models of inherited retinal degeneration caused by mutant opsin genes," <i>Inv. Ophth. Vis. Sci.</i> , 37:S698, Abstract, 1996.
▼	C40	Timmers, Newton and Hauswirth, "Synthesis and stability of retinal photoreceptor mRNAs are coordinately regulated during bovine fetal development," <i>Exp. Eye Res.</i> , 56:257-265, 1993.

EXAMINER: /Kimberly Chong/

DATE CONSIDERED: 09/11/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

O P E
SEP 20 2001

Page 5 of 6

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Atty. Docket No.
4300.014100Serial No.
09/847,601**Applicants**

Alfred S. Lewin, Lynn C. Shaw and Maria B. Grant

Filing Date:
May 1, 2001Group:
1632**U.S. Patent Documents**
*See Page 1***Foreign Patent Documents**
*See Page 1***Other Art**
*See Page 1-5***Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
KC	C41	van Ginkel and Hauswirth, "Parallel regulation of fetal gene expression in different photoreceptor cell types," <i>The Journal of Biological Chemistry</i> , 269(7):4986-4992, 1994.
	C42	Verma and Somia, "Gene therapy - promises, problems and prospects," <i>Nature</i> , 389:239-242, 1997.
	C43	von Weizsäcker, Blum and Wands, "Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template," <i>Biochemical and Biophysical Research Communications</i> , 189(2):743-748, 1992.
	C44	Xiao <i>et al.</i> , "Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector," <i>Journal of Virology</i> , 70(11):8098-8108, 1996.
	C45	Xing and Whitton, "An anti-lymphocytic choriomeningitis virus ribozyme expressed in tissue culture cells diminishes viral RNA levels and leads to a reduction in infectious viral yield," <i>Journal of Virology</i> , 67(4): 1840-1847, 1993.
	C46	Yu <i>et al.</i> , "A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1," <i>Proc. Natl. Acad. Sci. USA</i> , 90:6340-6344, 1993.
	C47	Yu <i>et al.</i> , "In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1," <i>Virology</i> , 206(1):381-386, 1995.
	C48	Yung, "Molecular modulation of vascular endothelial growth factor (VEGF) expression in glioma cells by ribozymes," <i>Neurology</i> , 48(3 Suppl. 2):A22, Abstract VI3.001, 1997.
	C49	Zolotukhin <i>et al.</i> , "A humanized green fluorescent protein cDNA adapted for high-level expression in mammalian cells," <i>Journal of Virology</i> , 70(7):4646-4654, 1996.
	C50	Co-pending U.S. Patent Application Serial No. 09/063,792, filed April 21, 1998 (4300.011400).
	C51	Report and recommendations of the panel to assess the NIH investment in research on gene therapy, Orkin and Motulsky, co-chairs, National Institutes of Health, December 1995.
	C52	Crooke, S.T., "Vitravene - Another piece in the mosaic," <i>Antisense and Nucleic Acid Devel.</i> , 8:vii-viii, 1998.
▼	C53	Gewirtz <i>et al.</i> , "Facilitating oligonucleotide delivery: Helping antisense deliver on its promise," <i>Proc. Natl. Acad. Sci. USA</i> , 93:3161-63, April 1996.

EXAMINER: /Kimberly Chong/

DATE CONSIDERED: 09/11/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

O 11 SEP 20 2001

Page 6 of 6

Form PTO-1449 (modified)

Atty. Docket No.
4300.014100Serial No.
09/847,601**List of Patents and Publications for Applicant's****INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicants

Alfred S. Lewin, Lynn C. Shaw and Maria B. Grant

Filing Date:

May 1, 2001

Group:

1632

U.S. Patent Documents*See Page 1***Foreign Patent Documents***See Page 1***Other Art***See Page 1-5***Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
KC	C54	Lyngstadaas <i>et al.</i> , "A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel <i>in vivo</i> ," <i>EMBO J.</i> , 14:5224-29, 1995
	C55	Stein, "Keeping the biotechnology of antisense in context," <i>Nat. Biotechnol.</i> , 17:209, March 1999
	C56	Stull <i>et al.</i> , "Antigene, ribozyme and aptamer nucleic acid drugs: Progress and prospects," <i>Pharm. Res.</i> , 12:465-83, April 1995
	C57	Christoffersen <i>et al.</i> , Ribozymes as human therapeutic agents," <i>J. Med. Chem.</i> , 38:2023-37, June 1995
↓	C58	LaVail <i>et al.</i> , "Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy," prepublished online as <i>Proc. Natl. Acad. Sci. USA Early Edition</i> , 10.1073/pnas210319397, September 26, 2000

EXAMINER: /Kimberly Chong/**DATE CONSIDERED:** 09/11/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.